Due to the high efficacy of BCR-ABL tyrosine kinase inhibition (TKI) in chronic phase (CP)
chronic myeloid leukemia (CML), the frequency of blast crisis (BC) is greatly reduced …

In recent years, structural and functional studies reveal that tyrosine kinases (TKs) act as the
essential components of signal transduction pathways that regulate cancer cell proliferation …

The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

Imatinib has so far been the first-choice treatment in chronic myeloid leukemia with excellent
results. However, only a proportion of patients achieve major molecular response–hence the …

Targeted therapy for chronic myeloid leukaemia (CML) has allowed for a near‐normal
patient life‐expectancy; however, quality of life and aggravation of existing co‐morbidities …

The primary goal of tyrosine kinase inhibitor (TKI) therapy for patients with chronic myeloid
leukemia is survival, which is achieved by the vast majority of patients. The initial response …

Among the novel and target-specific classes of anticancer drugs, small molecule tyrosine
kinase inhibitors (TKIs) represent an extremely promising and rapidly expanding group. TKIs …

Purpose Chronic myeloid leukemia (CML) patients are monitored by both cytogenetic and
molecular assessments, although present guidelines appear to switch from cytogenetic to …

Since the introduction of imatinib mesylate (IM) for the treatment of chronic myeloid leukemia
(CML), impressive clinical responses have been observed in the majority of patients in …

The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients
treated with imatinib and other tyrosine kinase inhibitors achieve lower levels of detectable …